Gentamicin injection

[04 January 2017]

Products Affected - Description

Gentamicin injection, Pfizer
40 mg/mL, 2 mL vial, 25 count (NDC 00409-1207-03)
60 mg/50 mL, premixed bag, 24 count )NDC 00409-7879-13)

Reason for the Shortage

Hospira has discontinued all premixed bags except for the 60 mg/50 mL size. This presentation is on long-term back order due to manufacturing delays.

Available Products

Gentamicin injection, Baxter
60 mg/50 mL, premixed bag, 24 count (NDC 00338-0507-41)
80 mg/50 mL, premixed bag, 24 count (NDC 00338-0509-41)
80 mg/100 mL, premixed bag, 24 count (NDC 00338-0503-48)
100 mg/50 mL, premixed bag, 24 count (NDC 00338-0511-41)
100 mg/100 mL, premixed bag, 24 count (NDC 00338-0505-48)
120 mg/100 mL, premixed bag, 24 count (NDC 00338-0507-48)
Gentamicin injection, Fresenius Kabi
10 mg/mL, 2 mL vial, 25 count (NDC 63323-0173-02)
40 mg/mL, 2 mL vial, 25 count (NDC 63323-0010-02)
40 mg/mL, 20 mL vial, 25 count (NDC 63323-0010-20)

Estimated Resupply Dates

Hospira has gentamicin 60 mg/50 mL premixed bags on back order and the company cannot estimate a release date. The 40 mg/mL 2 mL vials are available in limited supply.

Related Shortages


January 4, 2017; November 9, August 1, July 15, June 10, May 3, 2016, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing